Cancer, thrombosis and heparin-induced thrombocytopenia

Thrombosis Research

Volumn 120, Issue SUPPL. 2, 2007, Pages

  Prandoni, Paolo ^a   Falanga, Anna ^b   Piccioli, Andrea ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

Multiple myeloma; Thalidomide; Thromboprophylaxis; VTE

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ARTERY EMBOLISM; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL FEATURE; DISSEMINATED INTRAVASCULAR CLOTTING; ENDOCARDITIS; HEMATOLOGIC MALIGNANCY; HEMOSTASIS; HORMONAL THERAPY; HUMAN; MORBIDITY; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HEPARIN; HUMANS; NEOPLASMS; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

EID: 36049045718     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(07)70143-3     Document Type: Article

References (26)

1. Falanga A., Barbui T., Rickles F., and Levine M. Guidelines for clotting studies in cancer patients. Thromb Haemost 70 (1993) 343-350
2. Rickles F., and Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 102 (2001) V215-V224
3. Costantini V., and Zacharski L. Fibrin and cancer. Thromb Haemost 69 (1993) 406-414
4. Falanga A., and Donati M. Pathogenesis of thrombosis in patients with malignancy. Int J Hematol 73 (2001) 137-144
5. Varon D., and Brill A. Platelets cross-talk with tumor cells. Haemostasis 31 Suppl 1 (2001) 64-66
6. Grignani G., and Maiolo A. Cytokines and hemostasis. Haematolog-ica 85 (2000) 967-972
7. Falanga A., Marchetti M., Vignoli A., Balducci D., Russo L., Guerini V., and Barbui T. V617F JAK2 mutation in patients with Essential Thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 35 (2007) 702-711
8. Prandoni P., Falanga A., and Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 6 (2005) 401-410
9. Levitan N., Dowlati A., Remick S., Tahsildar H., Sivinski L., Beyth R., et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78 (1999) 285-291
10. Blom J., Doggen C., Osanto S., and Rosendaal F. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293 (2005) 715-722
11. Chew H., Wun T., Harvey D., Zhou H., and White R. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166 (2006) 458-464
12. Chew H., Wun T., Harvey D., Zhou H., and White R. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 25 (2007) 70-76
13. Sorensen H., Mellemkjaer L., Steffensen H., Olsen J., and Nielsen G. The risk of a diagnosis of cancer after primary deep-venous thrombosis or pulmonary embolism. N Engl J Med 338 (1998) 1169-1173
14. Baron J., Gridley G., Weiderpass E., Nyren G., and Linet M. Venous thromboembolism and cancer. Lancet 351 (1998) 1077-1080
15. Murchison J., Wylie L., and Stockton D. Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study. Br J Cancer 91 (2004) 92-95
16. White R., Chew H., Zhou H., Parikh-Patel A., Harris D., Harvey D., and Wun T. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 165 (2005) 1782-1787
17. Miller G., Bauer K., Howarth D., Cooper J., Humphries S., and Rosenberg R. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost 2 (2004) 2107-2114
18. Sorensen H., Pedersen L., Mellemkjaer L., Johnsen S., Skriver M., Olsen J., and Baron J. The risk of a second cancer after hospitalisation for venous thromboembolism. Br J Cancer 93 (2005) 838-841
19. Khorana A., Francis C., Culakova E., and Lyman G. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104 (2005) 2822-2829
20. Khorana A., Francis C., Culakova E., Kuderer N., and Lyman G. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5 (2007) 632-634
21. Barbui T., and Falanga A. Disseminated intravascular coagulation in acute leukemia. Semin Thromb Hemost 27 (2001) 593-604
22. Kwaan H., and Gordon L. Thrombotic microangiopathy in the cancer patient. Acta Hematologica 106 (2001) 52-56
23. Arepally G., and Ortel T. Heparin-induced thrombocytopenia. N Engl J Med 355 (2006) 809-817
24. Girolami B., Prandoni P., Stefani P., et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 101 (2003) 2955-2959
25. Prandoni P., Siragusa S., Girolami B., and Fabris F. The incidence of heparin-induced thrombocytopenia in medical patients treated with low molecular weight heparin. Blood 106 (2005) 3049-3054
26. Opatrny L., and Warner M. Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia. Am J Hematol 76 (2004) 240-244